Mark A. McCamish M.D., Ph.D.
Dr. Mark A. McCamish has been a member of the Avadel Board of Directors since December 2019. Dr. McCamish is currently the President and Chief Executive Officer of IconOVir Bio, a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer. Prior to IconOVir, Dr. McCamish served as President, Chief Executive Officer, and member of the Board of Directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company. From July 2009 to April 2017, Mark served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research, and academics. Mark received both a BA in physical education and an MA in ergonomics from the University of California at Santa Barbara, a PhD in nutritional sciences from Pennsylvania State University and an MD from University of California at Los Angeles.